



Global Pulmonary Arterial Hypertension (PAH) Market: Trends and Opportunities (2015-2019)

July 2015



Pulmonary Hypertension



Normal Heart

Global Pulmonary Arterial Hypertension (PAH) Market Report

Scope of the Report

The report titled "Global PAH Market: Trends and Opportunities (2015-2019)", analyzes the potential opportunities and significant trends in the global Pulmonary Arterial Hypertension (PAH) market. The market size and forecast in value terms for global PAH market has been provided for the period 2010 to 2019, considering 2014 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2015 to 2019. Over the next five years, Global PAH market revenue is forecasted to remain stable due to patent expiries and launch of new drugs.

The report provides detailed analysis of the global PAH market sizing and growth by type for the period 2010-2014. The market is further segment by drug mechanism and different dosage forms. The analysis of PAH individual drugs sales are also provided in the report.

The report profiles key market players such as Actelion Ltd., United Therapeutics Ltd. and SteadyMed Ltd. on the basis of attributes such as company overview, recent developments, strategies adopted by the market leaders to ensure growth, sustainability, financial overview and recent developments.

Company Coverage

- Actelion Limited
- United Therapeutics Limited
- SteadyMed Limited

PAH Drug Mechanism

- Endothelin Receptor Antagonists (ERA)
- PDE 5 Inhibitors
- Prostacyclins
- sGC Stimulator

Global Pulmonary Arterial Hypertension (PAH) Market Report

Executive Summary

Pulmonary Arterial Hypertension (PAH) is a disease in which high blood pressure occurs in the right ventricle of the heart and the pulmonary arteries that supply blood to the lungs. The increase in pressure is caused by constriction and narrowing of the small pulmonary arteries. In 2005, standard of care was characterized by intravenous treatment aimed at reducing symptoms, not addressing root cause. Now, new treatments are available that go beyond symptom management to treat the underlying cause of PAH. With advancement in the standard of care, patients are able to maintain active lifestyles with a reduced risk of serious heart events associated with PAH.


In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. Actelion developed the Tracleer and the sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015.

Despite an increase in per-member-per-year spend from 2013 to 2014; trend for medications used to treat pulmonary hypertension is expected to be sluggish again in 2015, chiefly because of the market saturation of generic sildenafil. The global PAH market is expected to achieve highest sales till now in the year 2017 due to imminent release of the PAH drug called Uptravi (Selexipag) in 2016, which is anticipated to potentially drive the growth of the total market till 2019. Popularity of combinational therapies is also likely to drive the market in the aforementioned period.


Global Pulmonary Arterial Hypertension (PAH) Market Report

It is estimated that PAH affects between x and xx individuals worldwide. Approximately x and xx people in U.S. and Europe respectively are affected with the PAH. The PAH market is expected continued growth due to higher incidence and improved diagnostic procedures.

Global PAH Market by Value; 2010-2014 (US\$ Billion)




Global Child Day Care Service Market Forecast: 2014-2019 (US\$ Billion)




The global PAH market is estimated to reach US\$.....billion in the year 2015, from an US\$.....billion in the year 2014. At the end of the forecasted period, i.e. 2019 the market is expected to reach to US\$.....billion, growing at a CAGR of% for the forecasted period i.e. 2015-2019.

Global PAH Market Analysis

Global Endothelin Receptor Antagonists (ERA) Market by Value; 2010-2014 (US\$ Million)



Global PDE 5 Inhibitors Market by Value; 2010-2014 (US\$ Million)



Global Prostacyclins Market by Value; 2010-2014 (US\$ Million)

